1,073 results on '"Schwartz, Lawrence H."'
Search Results
2. Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials
3. Three-Dimensional Margin as a Predictor of Local Tumor Progression after Microwave Ablation: Intraprocedural versus 4–8-Week Postablation Assessment
4. A machine-learning-based combination of criteria to detect bladder cancer lymph node metastasis on [18F]FDG PET/CT: a pathology-controlled study
5. A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)
6. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review.
7. Deep learning-based covert brain infarct detection from multiple MRI sequences
8. Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC
9. Predicting death or recurrence of portal hypertension symptoms after TIPS procedures
10. High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy
11. The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective
12. Effect of CT image acquisition parameters on diagnostic performance of radiomics in predicting malignancy of pulmonary nodules of different sizes
13. CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
14. Machine learning-based identification of contrast-enhancement phase of computed tomography scans
15. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G
16. Clinical Translation and Adaption
17. Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial
18. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
19. Quantitative Imaging in Cancer Clinical Trials
20. Recent Advances in the Field of Artificial Intelligence for Precision Medicine in Patients with a Diagnosis of Metastatic Cutaneous Melanoma
21. Multiparametric MRI in Era of Artificial Intelligence for Bladder Cancer Therapies
22. Artificial intelligence for aging research in cancer drug development
23. A Quantitative Multiparametric MRI Analysis Platform for Estimation of Robust Imaging Biomarkers in Clinical Oncology
24. Integrating [18F]-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography with Radiation Therapy and Immunomodulation in Precision Therapy for Solid Tumors
25. Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging
26. Solid Tumor Response Criteria
27. Radiomics
28. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4
29. A quantitative imaging biomarker for predicting disease-free-survival-associated histologic subgroups in lung adenocarcinoma
30. Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules
31. Determining the Variability of Lesion Size Measurements from CT Patient Data Sets Acquired under “No Change” Conditions
32. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
33. Assessment of response to treatment
34. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
35. Assessing immune response upon systemic RNA vaccination on [18F]-FDG PET/CT for COVID-19 vaccine and then for immuno-oncology?
36. Modeling Tumor Growth Using Partly Conditional Survival Models: A Case Study in Colorectal Cancer
37. Immunotherapy in the Treatment of Localized Genitourinary Cancers
38. Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma
39. The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI
40. When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
41. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis
42. Monitoring Responses to Therapy in Oncology
43. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
44. iRECIST: how to do it
45. Integrating [ 18 F]-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography with Radiation Therapy and Immunomodulation in Precision Therapy for Solid Tumors.
46. Quantitative imaging using CT
47. Differentiation of Focal-Type Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma Using Radiomics Based on Multiphasic Computed Tomography
48. Artificial intelligence in radiology
49. Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study
50. CCR Translation for This Article from A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.